Published in J Nucl Med on March 01, 2006
PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients. Int J Clin Oncol (2006) 1.16
SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates. BMC Cancer (2010) 1.12
A systematic review of PET and PET/CT in oncology: a way to personalize cancer treatment in a cost-effective manner? BMC Health Serv Res (2010) 1.00
Can multimodality imaging using 18F-FDG/18F-FLT PET/CT benefit the diagnosis and management of patients with pulmonary lesions? Eur J Nucl Med Mol Imaging (2010) 0.87
Long-Term Outcomes of Lobectomy for Non-Small Cell Lung Cancer After Definitive Radiation Treatment. Ann Thorac Surg (2015) 0.82
The advantage of PET and CT integration in examination of lung tumors. Int J Biomed Imaging (2007) 0.79
Metabolic profiling of plasma from benign and malignant pulmonary nodules patients using mass spectrometry-based metabolomics. Metabolites (2013) 0.79
Comparison of the diagnostic performance of (18)F-fluorothymidine versus (18)F-fluorodeoxyglucose positron emission tomography on pulmonary lesions: A meta analysis. Mol Clin Oncol (2014) 0.78
The rim sign: FDG-PET/CT pattern of pulmonary infarction. Insights Imaging (2012) 0.77
Thoracic staging with (18)F-FDG PET/MR in non-small cell lung cancer - does it change therapeutic decisions in comparison to (18)F-FDG PET/CT? Eur Radiol (2016) 0.77
Decreased levels of circulating sex hormones as a biomarker of lung cancer in male patients with solitary pulmonary nodules. Afr Health Sci (2014) 0.75
Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status. Oncotarget (2017) 0.75
Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA (2011) 6.92
Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med (2008) 4.71
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol (2012) 3.66
Clinical applications of PET in oncology. Radiology (2004) 3.44
Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med (2006) 3.15
Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol (2008) 2.96
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology (2012) 2.26
A comparative analysis of positron emission tomography and mediastinoscopy in staging non-small cell lung cancer. J Thorac Cardiovasc Surg (2003) 2.07
A comparison of the diagnostic accuracy of 18F-FDG PET and CT in the characterization of solitary pulmonary nodules. J Nucl Med (2008) 1.95
Neuroimaging and early diagnosis of Alzheimer disease: a look to the future. Radiology (2003) 1.87
Mammotomography with pinhole incomplete circular orbit SPECT. J Nucl Med (2003) 1.78
Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology (2012) 1.74
Impact of 18F-fluoride PET in patients with known prostate cancer: initial results from the National Oncologic PET Registry. J Nucl Med (2014) 1.68
Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. J Nucl Med (2008) 1.62
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol (2008) 1.59
Uric acid is a danger signal of increasing risk for osteoarthritis through inflammasome activation. Proc Natl Acad Sci U S A (2011) 1.59
Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med (2007) 1.57
First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med (2013) 1.51
Detection of primary breast carcinoma with a dedicated, large-field-of-view FDG PET mammography device: initial experience. Radiology (2005) 1.49
Impact of dedicated brain PET on intended patient management in participants of the national oncologic PET Registry. Mol Imaging Biol (2011) 1.49
Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol Aging (2012) 1.49
Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol (2002) 1.48
Impact of 18F-FDG PET used after initial treatment of cancer: comparison of the National Oncologic PET Registry 2006 and 2009 cohorts. J Nucl Med (2012) 1.47
Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol (2004) 1.45
Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro Oncol (2007) 1.39
PET studies of the influences of nicotine on neural systems in cigarette smokers. Am J Psychiatry (2003) 1.38
Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. J Clin Oncol (2008) 1.38
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol (2002) 1.32
Incidental detection of pigmented villonodular synovitis on FDG PET. Clin Nucl Med (2003) 1.32
NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw (2007) 1.26
NCCN task force: clinical utility of PET in a variety of tumor types. J Natl Compr Canc Netw (2009) 1.24
Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. Radiology (2003) 1.24
Positron emission tomography imaging of brain tumors. Neuroimaging Clin N Am (2002) 1.23
Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin. AJR Am J Roentgenol (2007) 1.16
The National Oncologic PET Registry (NOPR): design and analysis plan. J Nucl Med (2007) 1.15
Regional brain activity correlates of nicotine dependence. Neuropsychopharmacology (2007) 1.14
Receiver operating characteristic curves to assess predictors of radiation-induced symptomatic lung injury. Int J Radiat Oncol Biol Phys (2002) 1.14
Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol (2006) 1.12
Therapeutic angiogenesis in chronically ischemic porcine myocardium: comparative effects of bFGF and VEGF. Ann Thorac Surg (2004) 1.12
Incidence and patterns of neuraxis metastases in children with diffuse pontine glioma. J Neurooncol (2006) 1.11
Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med (2002) 1.09
The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry. Cancer (2009) 1.09
Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery (2003) 1.08
Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. J Nucl Med (2005) 1.08
Aging and attentional guidance during visual search: functional neuroanatomy by positron emission tomography. Psychol Aging (2002) 1.06
SNM practice guideline for lung scintigraphy 4.0. J Nucl Med Technol (2012) 1.06
Whole-body bone scintigraphy provides a measure of the total-body burden of osteoarthritis for the purpose of systemic biomarker validation. Arthritis Rheum (2009) 1.02
Left ventricular functional assessment in mice: feasibility of high spatial and temporal resolution ECG-gated blood pool SPECT. Radiology (2007) 1.00
Time course of tetrahydrocannabinol-induced changes in regional cerebral blood flow measured with positron emission tomography. Psychiatry Res (2002) 0.99
A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol (2008) 0.99
Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study. Neuro Oncol (2005) 0.98
Regional brain activation in response to rectal distension in patients with irritable bowel syndrome and the effect of a history of abuse. Dig Dis Sci (2003) 0.97
Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. Proc Natl Acad Sci U S A (2012) 0.95
Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates. J Neuropathol Exp Neurol (2014) 0.94
Depression and increased myocardial ischemic activity in patients with ischemic heart disease. Am Heart J (2003) 0.94
The time course of radiation therapy-induced reductions in regional perfusion: a prospective study with >5 years of follow-up. Int J Radiat Oncol Biol Phys (2002) 0.93
Prognosis after change in left ventricular ejection fraction during mental stress testing in patients with stable coronary artery disease. Am J Cardiol (2009) 0.93
Increasing uptake time in FDG-PET: standardized uptake values in normal tissues at 1 versus 3 h. Mol Imaging Biol (2008) 0.92
Cell therapy in murine atherosclerosis: in vivo imaging with high-resolution helical SPECT. Radiology (2007) 0.91
Procedure Guideline for SPECT/CT Imaging 1.0. J Nucl Med (2006) 0.91
Incremental prognostic power of single-photon emission computed tomographic myocardial perfusion imaging in patients with known or suspected coronary artery disease. Am J Cardiol (2005) 0.90
Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging. Int J Radiat Oncol Biol Phys (2012) 0.90
Positron emission tomography with 2-deoxy-2-[(18)F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer. Mol Imaging Biol (2004) 0.90
Practical approach to diagnostic CT combined with PET. AJR Am J Roentgenol (2007) 0.89
Clinical oncologic positron emission tomography: an introduction. Semin Roentgenol (2002) 0.89
Extrarenal retroperitoneal angiomyolipoma mimicking metastatic melanoma: CT and FDG PET correlation. Clin Nucl Med (2012) 0.88
Gated 99mTc-tetrofosmin and 18F-FDG studies: a comparison of single-acquisition and separate-acquisition protocols. J Nucl Med Technol (2002) 0.88
Outcome prediction in patients at high risk for coronary artery disease: comparison between 99mTc tetrofosmin and 99mTc sestamibi. Radiology (2004) 0.88
Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients. Cancer (2004) 0.88
Combination of converging collimators for high-sensitivity brain SPECT. J Nucl Med (2009) 0.86
Adult age differences in visual word identification: functional neuroanatomy by positron emission tomography. Brain Cogn (2002) 0.86
[18F]fluorodeoxyglucose-positron emission tomography in patients with medulloblastoma. Neurosurgery (2004) 0.86
Positron emission tomography with fluoro-2-deoxy-D-glucose (FDG-PET) in the staging of post transplant lymphoproliferative disorder in lung transplant recipients. J Thorac Imaging (2004) 0.84
The National Oncologic PET Registry: expanded medicare coverage for PET under coverage with evidence development. AJR Am J Roentgenol (2007) 0.83
Head and neck cancer: dedicated FDG PET/CT protocol for detection--phantom and initial clinical studies. Radiology (2007) 0.83
3'-Deoxy-3'-[F-18]fluorothymidine positron emission tomography in patients with recurrent glioblastoma multiforme: comparison with Gd-DTPA enhanced magnetic resonance imaging. Mol Imaging Biol (2006) 0.83
Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. Blood (2004) 0.82
Imaging of pheochromocytoma in 2 dogs using p-[18F] fluorobenzylguanidine. Vet Radiol Ultrasound (2002) 0.81
Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence. J Thorac Oncol (2007) 0.81
Positron emission tomography: lung cancer. Semin Roentgenol (2002) 0.81
Lexical and sublexical components of age-related changes in neural activation during visual word identification. J Cogn Neurosci (2003) 0.80
PET and brain tumor image fusion. Cancer J (2004) 0.80
Regional cardiac sympathetic innervation early and late after transmyocardial laser revascularization. J Card Surg (2004) 0.79
A comparison of mechanical and laser transmyocardial revascularization for induction of angiogenesis and arteriogenesis in chronically ischemic myocardium. J Am Coll Cardiol (2002) 0.79
ProstaScint (capromab pendetide) imaging using hybrid gamma camera-CT technology. AJR Am J Roentgenol (2005) 0.78
Impact of computed tomography-positron emission tomography fusion in staging patients with thoracic malignancies. Ann Thorac Surg (2002) 0.78
Does the preparation and utilization of 99mTc-sulfur colloid affect the outcomes of breast lymphoscintigraphy? J Nucl Med Technol (2013) 0.78
Clinical utility of positron emission tomography in the diagnosis and management of periampullary neoplasms. Ann Surg Oncol (2002) 0.78
Quantitative effects of contrast enhanced CT attenuation correction on PET SUV measurements. Mol Imaging Biol (2007) 0.78
Are discordant positron emission tomography and pathological assessments of the mediastinum in non-small cell lung cancer significant? J Thorac Cardiovasc Surg (2013) 0.77
Changes in plasma volume associated with mental stress ischemia in patients with coronary artery disease. Int J Psychophysiol (2005) 0.77
Medicare coverage of PET for cervical cancer. J Am Coll Radiol (2006) 0.76
The impact of urinary excretion of (18)F-labeled choline analogs. J Nucl Med (2007) 0.76
Prediction of death and nonfatal myocardial infarction in high-risk patients: a comparison between the Duke treadmill score, peak exercise radionuclide angiography, and SPECT perfusion imaging. J Nucl Med (2005) 0.75
Variable-time positron emission tomography leg protocol to equalize noise for positron emission tomography/computed tomography acquisitions. Nucl Med Commun (2011) 0.75
PET--elegant research tool now elegant clinical tool. Semin Roentgenol (2002) 0.75
PET appearance of tuberculous empyema necessitans. Clin Nucl Med (2011) 0.75